

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
KAESEMEYER : Confirmation No. 6530
Serial No. 10/763,309 : Group Art Unit: 1623
Filed: January 23, 2004 : Examiner: Lawrence E. Crane

For: PHARMACEUTICAL COMPOSITION COMPRISING CITRULLINE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The undersigned asserts that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP



Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
500 Grant Street, 50th Floor
Pittsburgh, PA 15219
Telephone: (412) 454-5000
Facsimile: (412) 281-0717
Date: June 21, 2007

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>					Complete if Known			
					Application Number		10/763,309	
					Filing Date		January 23, 2004	
					First Named Inventor		Kaesemeyer	
					Group Art Unit		1623	
					Examiner Name			
					Lawrence E. Crane			
Sheet 1 of 1		Attorney Docket Number			126625 00801			
U.S. PATENT DOCUMENTS								
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number	Kind Code (if known)					
FOREIGN PATENT DOCUMENTS								
Examiner's Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Office	Number				Kind Code (if known)	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T		
	C1	GENNARO ed., Remington's Pharmaceutical Sciences 18 th ed., 1990, Mack Publishing Co., Easton, PA (Table of Contents)						
	C2	BOYLAN et al. eds., Handbook of Pharmaceutical Excipients, 1986, Publ. by American Pharmaceutical Assoc., Washington, DC (Table of Contents)						
	C3	LIEBERMAN et al. eds., Pharmaceutical Dosage Forms, Tablets, 1990, Marcel Dekker, Inc., New York, NY (Table of Contents)						
	C4	DRAPER et al., Contrasting Effect of Nitric Oxide Sunthase Inhibition on LV Function During Early and Late Reoxygenation, International Society for Heart Research European Section XVIII European Section Meeting, Versailles, France, July 2-5, 1997, Journal of Molecular and Cellular Cardiology, pg. A97(Fr99)						
Examiner Signature				Date Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.